The full FDA approval of trastuzumab deruxtecan for HER2-mutant NSCLC in January 2026 marks the arrival of antibody-drug conjugates as a mainstream lung cancer treatment class, triggering a competitive ADC development wave across HER2, HER3, TROP2, and MET targets that is fundamentally reshaping the thoracic oncology commercial landscape. DESTINY-Lung02 trial data demonstrating a 49.0%...